REGEND001 clinical trials
Also written REGEND001.
How each study uses REGEND001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the REGEND001 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Regend Therapeutics (4) · Ruijin Hospital (2)
Studies
Open first, then newest update. How each study uses REGEND001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)Not yet recruitingPhase 3Regend TherapeuticsNCT07828353Written as REGEND001
- REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application StudyRecruitingPhase 1Ruijin HospitalNCT06987214Written as REGEND001 Autologous Basal Layer Stem Cell Suspension
- REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application StudyRecruitingPhase 1Ruijin HospitalNCT06998706Written as REGEND001 Autologous Basal Layer Stem Cell Suspension
- Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell TherapyCompletedPhase 2Regend TherapeuticsNCT05638776Written as REGEND001 cell therapy
- A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)CompletedPhase 2Regend TherapeuticsNCT06081621Written as REGEND001
- Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001CompletedPhase 1Regend TherapeuticsNCT05657184Written as REGEND001